(Circulation. 1997;95:860-867.)
© 1997 American Heart Association, Inc.
Articles |
Rapid and Simple Platelet Function Assay to Assess Glycoprotein IIb/IIIa Receptor Blockade
the Division of Hematology, Department of Medicine, Mount Sinai School of Medicine, New York, NY.
Background The platelet glycoprotein (GP) IIb/IIIa receptor antagonist c7E3 Fab (abciximab; ReoPro) has been approved as an antithrombotic agent, and other GP IIb/IIIa antagonists, including oral agents, are under development. At present, there are no rapid and simple assays to monitor GP IIb/IIIa receptor blockade.
Methods and Results An assay was devised based on the ability of platelets in whole blood to rapidly agglutinate fibrinogen-coated beads when stimulated with a peptide, (iso-S)FLLRN, that activates a platelet thrombin receptor but resists inactivation by plasma aminopeptidase M. Preincubation of normal blood with increasing concentrations of c7E3 Fab led to increasing inhibition of the assay, correlating with increased GP IIb/IIIa receptor blockade. Assay conditions were chosen so that agglutination was inhibited at 2 minutes when >82% of the receptors were blocked. Similar results were obtained with the use of GP IIb/IIIa antagonists based on the arginine-glycine-aspartic acid (RGD) cell-recognition sequence.
Conclusions A simple and rapid assay sensitive to GP IIb/IIIa receptor blockade has been developed that may be helpful in optimizing GP IIb/IIIa antagonist therapy.
Key Words: glycoproteins • receptors • platelets • fibrinogen
This article has been cited by other articles:
 |
|
 |
|
  W. Sun, C. Gerhardinger, Z. Dagher, T. Hoehn, and M. Lorenzi Aspirin at Low-Intermediate Concentrations Protects Retinal Vessels in Experimental Diabetic Retinopathy Through Non-Platelet-Mediated Effects Diabetes, December 1, 2005; 54(12): 3418 - 3426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Shanmugam Tirofiban and emergency coronary surgery Eur. J. Cardiothorac. Surg., October 1, 2005; 28(4): 546 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Altman, A. Scazziota, S. Santoro, and C. Gonzalez Abciximab Does Not Inhibit the Increase of Thrombin Generation Produced in Platelet-Rich Plasma In Vitro by Sodium Arachidonate or Tissue Factor Clinical and Applied Thrombosis/Hemostasis, July 1, 2005; 11(3): 271 - 277. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Brownlee Inaugural Article: Biography of Barry S. Coller PNAS, September 7, 2004; 101(36): 13111 - 13113. [Full Text] [PDF]
|
|
|
|
 |
|
 F.W.G. Leebeek, E. Boersma, C.P. Cannon, F.J.J. van de Werf, and M.L. Simoons Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable Eur. Heart J., March 2, 2002; 23(6): 444 - 457. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Samson and L. Shore-Lesserson Platelet Function and Cardiopulmonary Bypass Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 2001; 5(4): 273 - 281. [Abstract] [PDF]
|
|
|
|
|
|
G.A. Lanza, F. Andreotti, A. Sestito, A. Sciahbasi, F. Crea, and A. Maseri Platelet aggregability in cardiac syndrome X Eur. Heart J., October 2, 2001; 22(20): 1924 - 1930. [Abstract] [PDF]
|
|
|
|
|
|
L. Shore-Lesserson Monitoring the Hematologic Complications of Cardiopulmonary Bypass Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 207 - 216. [Abstract] [PDF]
|
|
|
|
 |
|
 M. J. Quinn, R. T. Murphy, M. Dooley, J. B. Foley, and D. J. Fitzgerald Occupancy of the Internal and External Pools of Glycoprotein IIb/IIIa following Abciximab Bolus and Infusion J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 496 - 500. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. P. Collet, G. Montalescot, C. Lesty, J. Soria, Z. Mishal, D. Thomas, and C. Soria Disaggregation of In Vitro Preformed Platelet-Rich Clots by Abciximab Increases Fibrin Exposure and Promotes Fibrinolysis Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 142 - 148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Abulencia, N. Tien, O. J. T. McCarty, D. Plymire, S. A. Mousa, and K. Konstantopoulos Comparative Antiplatelet Efficacy of a Novel, Nonpeptide GPIIb/IIIa Antagonist (XV454) and Abciximab (c7E3) in Flow Models of Thrombosis Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 149 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Chew and D. J. Moliterno A critical appraisal of platelet glycoprotein IIb/IIIa inhibition J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2028 - 2035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Despotis and L. T. Goodnough Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery Ann. Thorac. Surg., August 1, 2000; 70(2): S20 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Cannon, C. H. McCabe, R. G. Wilcox, A. Langer, A. Caspi, P. Berink, J. Lopez-Sendon, J. Toman, A. Charlesworth, R. J. Anders, et al. Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial Circulation, July 11, 2000; 102(2): 149 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Steinhubl, K. Kottke-Marchant, D. J. Moliterno, M. L. Rosenthal, N. K. Godfrey, B. S. Coller, E. J. Topol, and A. M. Lincoff Attainment and Maintenance of Platelet Inhibition Through Standard Dosing of Abciximab in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention Circulation, November 9, 1999; 100(19): 1977 - 1982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Quinn, A. Deering, M. Stewart, D. Cox, B. Foley, and D. Fitzgerald Quantifying GPIIb/IIIa Receptor Binding Using 2 Monoclonal Antibodies : Discriminating Abciximab and Small Molecular Weight Antagonists Circulation, May 4, 1999; 99(17): 2231 - 2238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Hu, C. A. White, S. Panzer-Knodle, J. D. Page, N. Nicholson, and J. W. Smith A New Model of Dual Interacting Ligand Binding Sites on Integrin alpha IIbbeta 3 J. Biol. Chem., February 19, 1999; 274(8): 4633 - 4639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Smith, S. R. Steinhubl, A. M. Lincoff, J. C. Coleman, T. T. Lee, R. S. Hillman, and B. S. Coller Rapid Platelet-Function Assay : An Automated and Quantitative Cartridge-Based Method Circulation, February 9, 1999; 99(5): 620 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.F. Storey, R.G. Wilcox, and S. Heptinstall Differential Effects of Glycoprotein IIb/IIIa Antagonists on Platelet Microaggregate and Macroaggregate Formation and Effect of Anticoagulant on Antagonist Potency : Implications for Assay Methodology and Comparison of Different Antagonists Circulation, October 20, 1998; 98(16): 1616 - 1621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Vorchheimer and V. Fuster Oral Platelet Glycoprotein IIb/IIIa Receptor Antagonists: The Present Challenge Is Safety Circulation, February 3, 1998; 97(4): 312 - 314. [Full Text] [PDF]
|
|
|
|
|
|
C. P. Cannon, C. H. McCabe, S. Borzak, T. D. Henry, M. D. Tischler, H. S. Mueller, R. Feldman, S. T. Palmeri, K. Ault, S. A. Hamilton, et al. Randomized Trial of an Oral Platelet Glycoprotein IIb/IIIa Antagonist, Sibrafiban, in Patients After an Acute Coronary Syndrome : Results of the TIMI 12 Trial Circulation, February 3, 1998; 97(4): 340 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Coller Monitoring Platelet GP IIb/IIIa Antagonist Therapy Circulation, January 13, 1998; 97(1): 5 - 9. [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Despotis, J. H. Joist, and L. T. Goodnough Monitoring of hemostasis in cardiac surgical patients: impact of point-of-care testing on blood loss and transfusion outcomes Clin. Chem., September 1, 1997; 43(9): 1684 - 1696. [Abstract] [Full Text] [PDF]
|
|